Appendix D: Included Studies adverse effects review
|
|
- Erica Barker
- 5 years ago
- Views:
Transcription
1 DELIRIUM APPENDICES (Draft for Consultation) Appendix D: Included Studies adverse effects review Table D1: Studies directly comparing two antipsychotic agents in delirium Author Study design Setting Age Male /Female Lee 2005 Randomized Treatment of controlled delirium in trial. No hospital blinding. Miyaji 2007 Skrobik 2004 Retrospective review of medical records. No blinding. Quasirandomized controlled trial. No blinding. Treatment of delirium in hospital Treatment of delirium in the critical care setting Drug & Dose Comparator Mean duration 61 20/20 Amisulpiride 156 mg daily (mean) Quetiapine 113mg daily (mean) Median /87 1. Oral haloperidol. Initial dose - median 0.75 (interquartile ) mg. Max dose - median 1.5 (interquartile ) mg. 2. Intravenous or intramuscular haloperidol. Initial dose - median 5 (interquartile 2.5-5) mg. Max dose - median 5 (interquartile ) mg /20 Olanzapine 5 mg (2.5mg for > 60 years) Risperidone Initial dose - median 0.5 (interquartil e 0.5-1) mg. Max dose - median 1 (interquartil e 0.5-2) mg. Haloperidol initiated at mg every 8 h, with lower dose 0.5-1mg for age >60 years. 7 days Median 11 days. Mainly for 1 day only Page 1 of 14
2 Table D1b: Studies directly comparing two antipsychotic agents in delirium (cohort studies) Author Study design Setting Age Male /Female Gill 2005 Cohort study Incidence of Mean 82.6 Atypical (retrospective ischaemic antipsyc and stroke in hotics prospective older adults 6424/11 elements). with 420 dementia antipsyc hotics 5797/90 Herrmann 2004 Cohort study (retrospective ). Incidence of stroke in older adults Mean antipsyc hotics 345/670 Risperid one 2159/48 05 Olanza pine 1061/23 60 Drug & Dose Risperidone (75.7%) Olanzapine (19.4%) Quetiapine (4.9%) High and low potency atypical antipsychotics prescribed Risperidone (61%) Olanzapine (30%) antipsychotics (9%) Mean duration Atypical days days 13,318 person years
3 DELIRIUM APPENDICES (Draft for Consultation) Table D2: Studies directly comparing two antipsychotic agents in delirium Author Lee 2005 Miyaji 2007 Methods used for AEs All adverse events were recorded but method not stated Two physicians checked case notes for any unfavourable sign, symptom or condition, or was listed as an adverse reaction in drug information leaflet, Events recorded irrespective of causality. Drug Comparator Drug AE details Comparator AE details Amisulpiride n=20 Oral haloperidol n=:95 IV/IM haloperidol: n=61 Quetiapine n=20 Risperidone : n=93 Oversedation - 1 Acute dystonia and dyskinesia were not observed Oversedation - 1 Acute dystonia and dyskinesia were not observed Haloperidol Oral IV/IM Control Excessive sedation 19 7 (11%) Excessive sedation 2 (2%) (20%) EPS EPS 2 (2%) (14%) (16%) Mortality during delirium 2 8 Mortality during delirium 3 (3.2%) (2.1%) (13.1%) Mortality within 1 yr after onset of delirium: 28 (29.5%) 28 (45.8%) Mortality within 1 yr after onset of delirium: 28 (30.1%) Hepatic function disorder Cerebral infarction Hypothermia 1 (1%) 1 (1%) 1 (1%) Convulsions 1 (1%) Skrobik 2004 Noted any use of antiparkinsonian medication for extrapyramidal side effects; Extrapyramidal signs were carefully recorded by physician using 2 scales Olanzapine n=45 Haloperidol n=28 Incidence of any AE 30 (31.4%) 20 (32.8%) Vital signs, and liver function tests were no different between groups. Patients on olanzapine had no extrapyramidal manifestations. Incidence of any AE: 6 (6.5%) For haloperidol, 6 patients noted to have low scores on extrapyramidal symptom testing (1 for the Ross Chouinard, 1-4 for the Simpson- Angus scale). No patient in either group received prophylactic or therapeutic antiparkinsonian therapy. Page 3 of 14
4 Gill 2005 Herrmann 2004 Patients were observed until they were admitted to hospital with ischaemic stroke, stopped taking their antipsychotic, died or the study ended Patients were observed until they were admitted to hospital for stroke, exposure to a medication from another study group, discontinuation of the drug, death or the end of the observation period Atypical n=17845 n=1015 n=14865 Risperidone n=6964 Olanzapine n=3421 Incidence of ischaemic stroke Incidence of stroke Incidence of ischaemic stroke Incidence of stroke
5 DELIRIUM APPENDICES (Draft for Consultation) Table D3: Study comparing all antipsychotics (typical and atypical) against control Author Study design Setting Age Male /Female Douglas 2008 Selfcontrolled not reporte case-series d Patients from the General Practice Research Database Median age to first exposure to any antipsychotic drug 80 Drug & Dose 1 Atypical antipsychotics: Risperidone (81%) Olanzapine (18%) Quetiapine (4%) Amisulpride (4%) antipsychotics: Phenothiazine (81%) Butyrophenone (20%) Thioxanthine (12%) Sulpride (3%) Mean duration Median duration of antipsychotic exposure 0.37 years (IQR 0.10 to 1.23) Author Methods used for AEs Drug Drug AE details Comparator AE details Douglas Atypical Incidence of stroke Incidence of stroke 2008 antipsychotics Intraperson comparisons in a population of individuals who have both the outcome (stoke) and exposure (antipsychotic) antipsychotics Page 5 of 14
6 Table D4: Studies comparing haloperidol against control in delirium Author Study design Setting Age Male Drug & Dose 1 Comparator Mean duration /Female Kalisvaart /172 Haloperidol 1.5mg daily Placebo 1-6 days (range) Kaneko 1999 Randomized, placebocontrolled, double-blind trial Randomized controlled trial. No blinding. Prevention of delirium in patients having hip surgery Prevention of delirium after GI surgery 72 24/14 Haloperidol 5 mg intravenous Saline 5 days Table D5: Studies comparing haloperidol against control in delirium Author Methods used for AEs Drug Comparator Drug AE details Comparator AE details Kalisvaart Haloperidol Placebo 218 Withdrawals due to AE: 3 Withdrawals due to AE: n=212 Kaneko 1999 Daily examination by the treating surgeons, spontaneous reports from the patients, and specific assessments; the Barnes Akathisia Scale and ECG, Daily BP, and assessment for sedation and extrapyramidal signs. Frequent reassessment of the patient s mental state and careful monitoring for side effects. Haloperidol n=40 Saline n=40 No drug-related side effects were seen during the study period. Values on the Barnes Akathisia Scale were 0 for all the patients in both groups. There was no sedation reported, Extrapyramidal side effects not noted with intervention; however, one patient who was administered haloperidol developed transient tachycardia. No other complication
7 DELIRIUM APPENDICES (Draft for Consultation) Table D6: Studies comparing atypical antipsychotics against control in delirium Author Study design Setting Age Male /Female Breitbart 2002 Open trial Treatment of mean 60.6, delirium in range hospitalized cancer patients Kim 2001 Open trial Treatment of delirium in hospital Pae 2004 Parellada 2004 Prakanratta 2007 Pilot trial, open label study Prospective multicentre observational in 5 hospitals Randomized, double blind, placebo controlled Treatment of delirium in hospital Treatment of delirium in hospital Prevention of delirium following cardiac surgery Mean 45.8 (SD 18.3), range (SD 9.8), range Drug & Dose Comparator Mean duration 40/39 Olanzapine. Mean starting dose 3 mg (range ). Dose after 2-3 days (T2) mean 4.6 mg (range ). Dose after 4-7 days (T3) mean 6.3mg (range ) 15/5 Olanzapine mean 5.9 (SD 1.5) mg/day. Initial mean 4.6 (SD 0.9) mg/day. Max mean 8.8 (SD2.2) mg/day 13/9 Quetiapine (flexible dose). Mean daily dose (SD 72.2) mg. Mean init. dose 37.5 (SD 12.8) mg/day. Mean max dose (SD 121) mg/day. None None None 4-7 days 67 40/24 Risperidone 2.6 mg (mean) None 7 days 6.6 (SD 1.7) days 8.5 (SD 4.5) days 61 74/52 Risperidone 1mg single dose Placebo Single dose Page 7 of 14
8 Table D7: Studies comparing atypical antipsychotics against control in delirium Author Breitbart 2002 Methods used for AEs Clinical (physical) examination Drug Comparator Drug AE details Comparator AE details Olanzapine n= 79 None Sedation 24 (30%) - reduced dosage for 8 pts. Rash, pruritus, nausea, stomach ache, dizziness, light headedness, blurred vision, headache: 3 (3.8%) Kim 2001 Not stated Olanzapine n=20 Pae 2004 Unclear Quetiapine n=22 Parellada 2004 Prakanratta 2007 UKU Side Effect Scale for psychotropic drugs (48 symptoms in psychiatric, neurological, autonomic and other domains). Investigator reports. Certain postoperative adverse outcomes were prespecified, but no mention of adverse effects monitoring Risperidone n=64 Risperidone n=63 Placebo n= 64 Withdrawals due to AE: 2 (2.5%) [Both patients who stopped due to AE (worsening delirium) were > 80 yrs] None Mild sedation, dry mouth: 2 None EPS, dyskinesia, dystonia: 0 Mild sedation: 3 Withdrawals due to AE: 1 (4%). (due to sedation) None Total AEs: 5 Drowsiness - 2 (3.1%) Nausea - 1 (1.6%) Acute renal failure - 1 Seizure -1 Postoperative adverse outcomes: Renal Failure - 1 (3.2%) Respiratory Failure - 1 (3.2%) Arrhythmia - 1 (9.5%) Cardiovascular instability - 3 (4.8%) Tracheal re-intubation - 0 Postoperative adverse outcomes: Renal Failure - 3 (4.8%) Respiratory Failure - 4 (6.3%) Arrhythmia - 6 (9.5%) Cardiovascular instability 4 (6.3%) Tracheal re-intubation - 4 (6.3%)
9 DELIRIUM APPENDICES (Draft for Consultation) Table D8: Study comparing cholinesterase inhibitors against control in delirium Author Setting Study design Age Male/Female Drug & Dose Mean duration Comparator Liptzin 2005 Prevention or treatment of delirium in patients having joint replacement surgery Randomized double blind placebo controlled /46 Donepezil 5mg once daily 28 days Placebo Table D9: Study comparing cholinesterase inhibitors against control in delirium Methods used for AEs Drug Comparator Drug AE details Comparator AE details Liptzin 2005 Not stated Donepezil n=39 Placebo n=41 No difference in the rate of discontinuation. More than 25% of subjects took less than 28 days of assigned treatment. This was apparently not due to side effects, as rates (of side effects) were equivalent between drug and placebo. Table D10: Study comparing ondansetron against control in delirium Author Study design Setting Age Male Drug & Dose Comparator Mean duration /Female Bayindir 2000 Open label uncontrolled trial Treatment of post cardiotomy delirium 51 23/15 Ondansetron 8 mg iv None Single dose Table D11: Study comparing ondansetron against control in delirium Author Bayindir 2000 Methods used for AEs Not stated. Drug Comparator Drug AE details Comparator AE details Ondansetron n=35 None No constipation, headache, extrapyramidal effects, or rise in liver enzymes were observed in this study. It is safe, effective and without apparent side effects. Page 9 of 14
10 Table D12: Studies reporting on stroke adverse events Reference Gill et al., (BMJ 2005) Study type/ Evidence level Cohort study (retrospective and prospective elements) Canada Number of patients Total N=32710 (17,845 atypical antipsycotic s; 14,865 typical antipsychot ics) Patient characteristics Exposed Unexposed Length of follow-up Inclusion criteria: Older adults with dementia (Ontario Health Insurance plan and ICD-9 codes 290, 331 and 797); 2 cohorts: those who were new users of any of 3 atypical antipsychotics (risperidone, olanzapine and quetiapine) and those who were new users of either high potency typical antipsychotics or low potency typical antipsychotics. Exclusion criteria: Patients receiving non-oral antipsychotics or those with other psychotic disorders that may affect their pattern of drug use. Excluded patients taking antipsychotic drug clozapine as this was rarely used at the time of the study in Ontario. Not included cohort of nonantipsychotic users as preliminary data show several important baseline differences between patients receiving antipsychotics and those not receiving antipsychotics. Not include cohorts of patients taking other psychotropics for BPSD such as trazadone or valproate, as these are used for other indications. Baseline Atypical antipsyc hotics (N=1784 5) antispyc hotics (N=1486 5) Mean age 82.5 (7.3) 82.7 (7.4) (years) Men/women 36%/64% 39%/61% Risperidone Olanzapine Quetiapine 75.7% 19.4% 4.9% vs atypical antipsychotics Mean duration of follow-up: (264) days for atypical group; (335.4) for typical group. Patients were observed until they were admitted to hospital with ischaemic stroke, stopped taking their antipsychot ic, died or the study ended. Outcome measures Primary outcome: admission to hospital with a most responsible diagnosis of ischaemic stroke Source of funding Grant from Departm ent of Veterans Affairs, USA.
11 DELIRIUM APPENDICES (Draft for Consultation) Reference Study type/ Evidence level Effect size Outcome measure Number of patients Patient characteristics Exposed Unexposed Length of follow-up Atypical antipsychotics (N=17845) antispychotics (N=14865) Total population (main analysis) Number (%) of new admissions for ischaemic stroke 284 (1.6) 227 (1.5) Number of events per 1000 person years Adjusted HR* 1.01 (95%CI 0.81 to 1.26) 1.0 (reference) Subgroup analyses Outcome measures Source of funding 1. History of stroke Number (%) of new admissions for ischaemic stroke 103 (7.7) 75 (6.3) Number of events per 1000 person years Adjusted HR* 0.8 (0.55 to 1.16) Long-term care resident at baseline Number (%) of new admissions for ischaemic stroke 124 (1.5) 98 (1.3) Number of events per 1000 person years Adjusted HR* 1.15 (0.82 to 1.60) Chronic users Number (%) of new admissions for ischaemic stroke 214 (1.6) 163 (1.6) Number of events per 1000 person years Adjusted HR* 0.89 (0.69 to 1.17) History of AF Number (%) of new admissions for ischaemic stroke 52 (2.6) 34 (2.0) Number of events per 1000 person years Adjusted HR* 1.23 (95%CI 0.70 to 2.02) 1.0 *Multivariate analysis (Cox proportional hazards models) adjusted for confounders: age; gender; low income; residence in long-term care; frequency of medical contact; medical conditions such as prior stroke in past 5 years, history of AF, hypertension, diabetes, acute MI in past 3 months, congestive heart failure; number of distinct drugs; chronic use of antipsychotics ( 2 consecutive prescriptions); overall burden from comorbid disease; concomitant use of drugs that may influence the risk of stroke or recognition; year of entry to the study. Page 11 of 14
12 Reference Douglas et al (BMJ 2008) Study type/ Evidence level Self-controlled case-series* UK (patients from GPRD General Practice Research Database) *Selfcontrolled case-series method (intraperson comparisons in a population of individuals who have both the outcome and exposure of interest. Rate ratios compare the rate of events during exposed periods of time with the rate during all other observed time periods. This removes the potential effect of confounding characteristics that vary between individuals and risk factors for vascular disease. Number of patients Total N=6790 (n=905 atypical antipsychot ic, n=6334 typical antipsychot ic drug) Patients with dementia: Total n=1423 (n=1208 typical antipsych otic, n=85 atypical antipsych otic drug) Patient characteristics Exposed Unexposed Length of follow-up Inclusion criteria: all patients with a first ever incident diagnosis of stroke at least 12 months after initial registration with the database. Had to have the incident of stroke before Dec 2002 and also to have been prescribed at least 1 antipsychotic medicine before this date (this was done to eliminate possible changes in prescribing pattern as concerns of AEs in elderly arose around this time) Median age to first exposure to any antipsychotic drug was 80. Most common atypical antipsychotic drug was risperidone (n=729) Risperidone Olanzapine Quetiapine Amisulpride 81% 18% 4% 4% and atypical antipsychotics versus no treatment Median duration of antipsychotic exposure 0.37 (IQR 0.10 to 1.23) years Outcome measures Association between exposure to antipsychoti cs and Stroke Source of funding MRC of Canada
13 DELIRIUM APPENDICES (Draft for Consultation) Reference Study type/ Evidence level Number of patients Patient characteristics Exposed Unexposed Length of follow-up Outcome measures Source of funding Effect size Outcome measure (rate ratio association between exposure Any antipsychotic (N=1423) antipsychotics (N=1208) Atypical antipsychotics (N=85) and stroke) All patients Exposed vs unexposed periods 1.73 (1.60 to 1.87) 1.69 (1.55 to 1.84) 2.32 (1.73 to 3.10) Patients with recorded dementia (n=1423) Exposed vs unexposed periods 3.50 (2.97 to 4.12) 3.26 (2.73 to 3.89) 5.86 (3.01 to 11.38) Days after treatment (3.34 to 4.87) 3.74 (3.05 to 4.59) 5.70 (2.50 to 12.98) (2.33 to 3.96) 2.92 (2.20 to 3.88) 4.41 (1.40 to 13.89) (1.97 to 3.73) 2.40 (1.69 to 3.41) 3.50 (0.76 to 16.25) (1.45 to 3.15) 2.16 (1.44 to 3.23) 2.21 (0.28 to 17.34) (0.95 to 2.44) 1.49 (0.90 to 2.44) 2.40 (0.30 to 18.88) Page 13 of 14
14 Reference Herrmann et al, (Am J Psychiatry 2004) Study type/ Evidence level Cohort study (retrospective) Canada Number of patients Total N=11400 (1015 typical antipsycotic s; 6964 risperidone; 3421 olanzapine) Patient characteristics Exposed Unexposed Length of follow-up Inclusion criteria: individuals 66 years old who were given at least 2 successive prescriptions and received enough drug for 30 days of observation. Duration of exposure was the period of continuous, exclusive use of any of the study drugs starting from the index date. Hospital admissions for stroke were identified using ICD codes (430, 431, 434, 435 and 436). Baseline antipsyc hotics (N=1015) Risperid one (N=6964) Olanzapi ne (N=3421) Mean age 81.1 (7.8) 82.9 (7.1) 81.2 (7.5) (years) Men/women 34%/66% 31%/69% 31%/69% vs atypical antipsychotics (reference) 13,318 person years of follow-up Follow-up ended with hospital admission for stroke, exposure to a medication from another study group, discontinu ation of the drug, death or end of the observatio n period. Outcome measures Risk of stroke Source of funding None mentione d Effect Size Risk ratio for stroke: 1.1 (0.5 to 2.3) with olanzapine use 1.4 (0.7 to 2.8) with risperidone use Relative to olanzapine, users of risperidone were not at significantly increased risk of stroke-related hospital admission: adjusted risk ratio 1.3 (0.8 to 2.2) Multivariate analysis (Cox proportional hazards model) adjusted for hospitalisations, procedures, drug utilisation hypothesised to be associated with the risk of stroke as well as basic demographic characteristics. The number of prescription drugs dispensed in the year before the index date was included as a measure of overall comorbidity.
Antipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationUse of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia
Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia Aine Leen, Kieran Walsh, David O Sullivan, Denis O Mahony, Stephen Byrne, Margaret Bermingham Pharmaceutical Care Research Group,
More informationNew Medications in Early Psychosis
New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,
More informationCambridge University Press Effective Treatments in Psychiatry Peter Tyrer and Kenneth R. Silk Excerpt More information
Organic disorders 1 Delirium Based on Delirium by Laura Gage and David K. Conn in Effective Treatments in Psychiatry, Cambridge University Press, 2008 Introduction Delirium needs treatment for both its
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationDatix Ref:
Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document
More informationANTIPSYCHOTICS AGENTS CONVENTIONAL
ANTIPSYCHOTICS AGENTS CONVENTIONAL Documentation A. FDA approved indications 1. Psychotic Disorder (Haloperidol, Thiothixene) 2. Schizophrenia 3. Bipolar Disorder, Manic (Chlorpromazine) 4. Severe Behavioral
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More informationRESEARCH. Exposure to antipsychotics and risk of stroke: self controlled case series study
Exposure to antipsychotics and risk of stroke: self controlled case series study Ian J Douglas, research fellow, Liam Smeeth, professor of clinical epidemiology Department of Epidemiology and Population
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationSYNOPSIS. Trial identification and protocol summary
SYNOPSIS Trial identification and protocol summary Company: JANSSEN PHARMACEUTICA N.V. Finished product: Risperdal Active ingredient: Risperidone (R64766) Title: The safety and efficacy of risperidone
More informationDosing & Administration
Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some
More informationESSENTIAL SHARED CAR E AGREEMENT FOR
E093 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in People with Learning Disability (LD) Referral Criteria In some
More informationHearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds
Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction
More informationDELIRIUM IN ICU: Prevention and Management. Milind Baldi
DELIRIUM IN ICU: Prevention and Management Milind Baldi Contents Introduction Risk factors Assessment Prevention Management Introduction Delirium is a syndrome characterized by acute cerebral dysfunction
More informationPharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:
0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationMental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service
Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact
More informationTHIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes
THIOTHIXENE THERAPEUTICS Brands Navane see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist) Commonly Prescribed for (bold
More informationPsychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson
Psychotropic Drug Therapy in Adults with Learning Disability Steve Wilkinson Outline and Aims of the Session Drug use in learning disability Two distinct areas of drug therapy I. Treatment of common psychiatric
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)
E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine
Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationAntidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych
Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych A. Heterocyclic antidepressants: (tricyclic and tetracyclic ), e.g.amitryptaline,imipramine. B. Monoamine oxidase inhibitors(m.a.o.i), e.g.phenelzine.
More informationSilvia Duong, 1,2 Kam-Tong Yeung, 1 and Feng Chang 1,3. 1. Introduction
Aging Research Volume 2015, Article ID 570410, 6 pages http://dx.doi.org/10.1155/2015/570410 Research Article Intramuscular Olanzapine in the Management of Behavioral and Psychological Symptoms in Hospitalized
More informationVersion 5.1: June ZYPADHERA Olanzapine powder & solvent for prolonged release suspension for injection
ZYPADHERA Olanzapine powder & solvent for prolonged release suspension for injection Patients Treated with Depot Antipsychotics May.. Have had multiple relapses and/or recent hospitalizations Have a history
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD
Ref No: E050 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Please complete the following details: Patient s name,
More informationCanadian Practices for the Treatment of Delirium. Lisa Burry, BScPharm, PharmD
Canadian Practices for the Treatment of Delirium Lisa Burry, BScPharm, PharmD Disclosures & Acknowledgements Conflicts of interest: None Acknowledgements: our patients and the clinical staff that supported
More informationNausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.
Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More information) and serotonin Type 2 (5-HT 2A
Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationChoice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review
Pratt et al. BMC Medical Research Methodology 2012, 12:72 RESEARCH ARTICLE Open Access Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationDelirium. Assessment and Management
Delirium Assessment and Management Goals and Objectives Participants will: 1. be able to recognize and diagnose the syndrome of delirium. 2. understand the causes of delirium. 3. become knowledgeable about
More informationPSYCHOTROPIC SOLUTIONS
PSYCHOTROPIC SOLUTIONS A proactive approach to antipsychotic medication management A Quality Use of Medicines initiative by Choice Aged Care Copyright 2018 Key Senate Committee Recommendations: All RACF
More informationPERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes
PERPHENAZINE THERAPEUTICS Brands Trilafon see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Conventional antipsychotic (neuroleptic,
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRisks of Antipsychotics use In Dementia
AHCA/NCAL Quality Initiative for Assisted Living Webinar Series: Safely Reducing the Off-Label Use of Antipsychotics Risks of Antipsychotics use In Dementia Sanjay P. Singh, MD Chairman & Professor, Department
More informationPERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes
PERPHENAZINE THERAPEUTICS Brands Trilafon see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist, antiemetic) Commonly Prescribed
More informationThe Agitated. Older Patient: old. What To Do? Michelle Gibson, MD, CCFP Presented at Brockville General Hospital Rounds, May 2003
Focus on CME at Queen s University Focus on CME at Queen s University The Agitated The Older Patient: What To Do? Michelle Gibson, MD, CCFP Presented at Brockville General Hospital Rounds, May 2003 Both
More informationJanssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V.
SYNOPSIS Issue Date: Final 22 July 2009 [Document No.: EDMS-PSDB-9245102] Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-BMN-3001 Janssen-Cilag
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationFirst Steps: Considering Clozapine for your Patients
First Steps: Considering Clozapine for your Patients The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health
More informationCognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics
Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationIs Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Aristada (Aripiprazole Lauroxil)
More informationUse of Psychotherapeutic Medications in Children and Adolescents with ASD and ID
Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID Although not considered first line treatment in children with ASD and ID, depending on the severity of symptoms, some medications
More informationPsychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan Pretest 1. Appropriate target symptoms for emergency room medication treatment
More informationSYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:
SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled
More informationOlanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
More informationPresented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationScottish Medicines Consortium
Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish
More informationSYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95
SYNOPSIS Trial identification and protocol summary Company: Janssen Research Foundation Finished product: RISPERDAL Active ingredient: Risperidone (R064,766) Title: An open-label, long-term study of risperidone
More informationA systematic review of atypical antipsychotic drugs in schizophrenia. Atypical antipsychotic drugs in schizophrenia
A systematic review of atypical antipsychotic drugs in schizophrenia Atypical antipsychotic drugs in schizophrenia A-M Bagnall 1 * S Gilbody 3 L Jones 1 L Davies 4 L Ginnelly 2 D Torgerson 2 R Lewis 1
More informationAntipsychotic Use in the Elderly
Antipsychotic Use in the Elderly Presented by: Fatima M. Ali, PharmD, RPh, BCPS Clinical Consultant Pharmacist MediSystem Pharmacy, Kingston Originally Prepared by: Nicole Tisi BScPhm, RPh ACPR Disclosure
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More information9: 3 TABLE OF CONTENTS P&T
Vol 9: No 3 TABLE OF CONTENTS Short-term Safety of Antipsychotics for Dementia 1-2 Preoperative Statins and Effects on Mortality 2-4 Hormone Replacement Therapy and Risk of Venous Thromboembolism 4-5 P&T
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationTRIFLUOPERAZINE. THERAPEUTICS Brands Stelazine see index for additional brand names
TRIFLUOPERAZINE THERAPEUTICS Brands Stelazine see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Conventional antipsychotic (neuroleptic,
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationVI.2 Elements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Incidence and prevalence of target indication Schizophrenia is a mental disorder characterized by a breakdown of thought processes
More informationSupplementary Online Content
Supplementary Online Content Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. Published online August 17, 2016.
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationTreatment of Children and Adolescents with Schizophrenia
Treatment of Children and Adolescents with Schizophrenia The evidence base pertaining to the pharmacotherapy of schizophrenia in children and adolescents (C&A) is tiny compared to what is available for
More informationMEDICATIONS PRESCRIPTION AT HOSPITAL DISCHARGE IN PATIENTS WITH VALIDATED DIAGNOSIS OF DEMENTIA. Federica Edith Pisa University Hospital Udine
MEDICATIONS PRESCRIPTION AT HOSPITAL DISCHARGE IN PATIENTS WITH VALIDATED DIAGNOSIS OF DEMENTIA Federica Edith Pisa University Hospital Udine BACKGROUND Polypharmacy and psychotropic medication use are
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationDelirium Monograph - Update, Spring 2014
Delirium Monograph - Update, Spring 2014 Since publication of the APM monograph on Delirium in January 2012, three structured reviews have been published adding data relevant to the practice of identification,
More informationGeriatric Pharmacology
Geriatric Pharmacology Janice Scheufler R.Ph.,PharmD, FASCP Clinical Pharmacist Hospice of the Western Reserve Objectives List three risk factors for adverse drug events in the elderly Discuss two physiological
More informationDrugs used in schizophrenia قادة فریق علم الا دویة : الشكر موصول لا عضاء الفریق المتمیزین :
MCQs SAQs Summar y Drugs used in schizophrenia قادة فریق علم الا دویة : لین التمیمي & عبدالرحمن ذكري الشكر موصول لا عضاء الفریق المتمیزین : روان سعد القحطاني فؤاد بھجت عبدالرحمن العریفي حاتم النداح pharma436@outlook.com
More informationMORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE
MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE KRISTA L. LANCTÔT, PHD PROFESSOR OF PSYCHIATRY AND PHARMACOLOGY, UNIVERSITY OF TORONTO; SENIOR SCIENTIST, HURVITZ BRAIN
More informationDosing and administration information for ABILIFY MAINTENA (aripiprazole)
DOSING AND ADMINISTRATION GUIDE Dosing and administration information for ABILIFY MAINTENA (aripiprazole) Approved for deltoid or gluteal administration ABILIFY MAINTENA (aripiprazole) is an atypical antipsychotic
More informationPsychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan Pretest 1. Which of the following conditions is LEAST likely to benefit from emergency
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis The Harvard community has made
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationAPO-ARIPIPRAZOLE. Aripiprazole Tablets, USP. 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Antipsychotic agent. Date of Revision: March 6, 2018
Pr APO-ARIPIPRAZOLE Aripiprazole Tablets, USP 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg Antipsychotic agent APOTEX INC. 150 Signet Drive Toronto, Ontario Canada, M9L 1T9 Date of Revision: March 6, 2018
More informationShared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults
Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no:
More informationRIVA-ARIPIPRAZOLE PRODUCT MONOGRAPH. Aripiprazole Tablets, House Standard. 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Antipsychotic Agent
PRODUCT MONOGRAPH Pr RIVA-ARIPIPRAZOLE Aripiprazole Tablets, House Standard 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg Antipsychotic Agent Laboratoire Riva Inc. 660 Boul. Industriel Blainville, Québec J7C
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 1 February 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 1 February 2012 XEPLION 25 mg, prolonged-release suspension for injection 1 pre-filled polycycloolefin syringe with
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationAHA Clinical Science Special Report: November 10, 2015
www.canheart.ca High-density lipoprotein cholesterol and cause-specific mortality: A population-based study of more than 630,000 individuals without prior cardiovascular conditions Dennis T. Ko, MD, MSc;
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information